ArticleCancer chemotherapy and pharmacology2016

A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.

Klaus Mross et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.